Author details

Full Name

Yisong Wang

Affiliation

Lombardi Comprehensive Cancer Center, Georgetown University

ORCID

Career Start Year

2010

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
32034314	Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells.	Cell Death Differ	2020
32034314	Mutant GTF2I induces cell transformation and metabolic alterations in thymic epithelial cells.	Cell Death Differ	2020
29413049	High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.	Lung Cancer	2018
29413049	High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.	Lung Cancer	2018
28819023	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.	Cancer Res	2017
28819023	Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.	Cancer Res	2017
28765579	Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.	Sci Rep	2017
28765579	Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.	Sci Rep	2017
27078848	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.	Oncotarget	2016
27078848	CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.	Oncotarget	2016
27117832	PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.	J Thorac Oncol	2016
26639656	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.	Mol Oncol	2016
26639656	EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.	Mol Oncol	2016
27117832	PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.	J Thorac Oncol	2016
25592632	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.	Lancet Oncol	2015
25592632	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.	Lancet Oncol	2015
25667274	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	J Clin Oncol	2015
26324742	Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling.	Clin Cancer Res	2015
26324742	Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling.	Clin Cancer Res	2015
25667274	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	J Clin Oncol	2015
24166505	HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.	Oncogene	2014
25482724	Mutations of epigenetic regulatory genes are common in thymic carcinomas.	Sci Rep	2014
24166505	HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.	Oncogene	2014
24301457	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.	J Natl Cancer Inst	2014
24911146	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.	J Clin Invest	2014
24852181	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.	J Mol Med (Berl)	2014
24974848	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.	Nat Genet	2014
24736083	Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.	J Thorac Oncol	2014
25482724	Mutations of epigenetic regulatory genes are common in thymic carcinomas.	Sci Rep	2014
24974848	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.	Nat Genet	2014
24736083	Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.	J Thorac Oncol	2014
24852181	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.	J Mol Med (Berl)	2014
24911146	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.	J Clin Invest	2014
24301457	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation.	J Natl Cancer Inst	2014
23131389	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.	Ann Oncol	2013
22973954	Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.	Curr Pharm Des	2013
24158701	The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.	Clin Cancer Res	2013
23979919	Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.	Mol Cancer Ther	2013
23444221	Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.	Clin Cancer Res	2013
23131389	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.	Ann Oncol	2013
23577124	Whole genome and transcriptome sequencing of a B3 thymoma.	PLoS One	2013
24158701	The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.	Clin Cancer Res	2013
23979919	Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.	Mol Cancer Ther	2013
23444221	Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.	Clin Cancer Res	2013
23577124	Whole genome and transcriptome sequencing of a B3 thymoma.	PLoS One	2013
22973954	Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.	Curr Pharm Des	2013
22128300	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.	Clin Cancer Res	2012
22891268	Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.	J Clin Oncol	2012
22425924	NUT rearrangement is uncommon in human thymic epithelial tumors.	J Thorac Oncol	2012
22825469	Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.	Cell Death Dis	2012

1 - 50 of 72

Yang Shao

Nanjing Geneseeq Technology Inc.

Career Start Year 2012

Number of shared co-authors 0

Siddhartha Devarakonda

Siteman Cancer Center, Washington University School of Medicine

Career Start Year 2011

Number of shared co-authors 1

Caroline E McCoach

UCSF Helen Diller Comprehensive Cancer Center

Career Start Year 2009

Number of shared co-authors 0

Ashiq Masood

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Career Start Year 2008

Number of shared co-authors 0

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Career Start Year 2008

Number of shared co-authors 1

John T Poirier

Laura and Isaac Perlmutter Cancer Center

Career Start Year 2007

Number of shared co-authors 1

Li Liu

Central South University

Career Start Year 2006

Number of shared co-authors 0

Martin L Sos

University of Cologne, Faculty of Medicine and University Hospital Cologne

Career Start Year 2005

Number of shared co-authors 0

Ming Li

Princess Margaret Cancer Centre, University Health Network

Career Start Year 2003

Number of shared co-authors 0

Lixia Diao

The University of Texas MD Anderson Cancer Center

Career Start Year 2003

Number of shared co-authors 0

Lecia V Sequist

Massachusetts General Hospital Cancer Center, Harvard Medical School

Career Start Year 2003

Number of shared co-authors 1

Trever G Bivona

University of California san francisco

Career Start Year 2002

Number of shared co-authors 0

Daniel Morgensztern

Washington University School of Medicine

Career Start Year 2000

Number of shared co-authors 0

Benjamin Solomon

Peter MacCallum Cancer Centre

Career Start Year 2000

Number of shared co-authors 1

Collin M Blakely

University of California san francisco

Career Start Year 1998

Number of shared co-authors 0

Anthony J Iafrate

Massachusetts General Hospital

Career Start Year 1997

Number of shared co-authors 2

Peter S Hammerman

Novartis Institutes for BioMedical Research

Career Start Year 1996

Number of shared co-authors 0

Siraj M Ali

Foundation Medicine

Career Start Year 1995

Number of shared co-authors 3

Michael Peyton

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center

Career Start Year 1994

Number of shared co-authors 0

Gregory J Riely

Memorial Sloan Kettering Cancer Center

Career Start Year 1994

Number of shared co-authors 3

Vincent A Miller

Injury Prevention Research Center, University of North Carolina

Career Start Year 1994

Number of shared co-authors 2

Ultan McDermott

Wellcome Sanger Institute

Career Start Year 1993

Number of shared co-authors 1

E Alejandro Sweet-Cordero

University of California San Francisco

Career Start Year 1989

Number of shared co-authors 1

Charles M Rudin

Memorial Sloan Kettering Cancer Center

Career Start Year 1989

Number of shared co-authors 2

Pasi A J??nne

Dana-Farber Cancer Institute

Career Start Year 1986

Number of shared co-authors 4

Roy S Herbst

Yale School of Medicine

Career Start Year 1984

Number of shared co-authors 1

Marc Ladanyi

Memorial Sloan Kettering Cancer Center

Career Start Year 1984

Number of shared co-authors 7

Ramaswamy Govindan

Siteman Cancer Center, Washington University School of Medicine

Career Start Year 1981

Number of shared co-authors 1

Antonio Jimeno

University of Colorado School of Medicine

Career Start Year 1974

Number of shared co-authors 0

Ming-Sound Tsao

University Health Network, University of Toronto

Career Start Year 1972

Number of shared co-authors 2

row(s) 1 - 30 of 30

Giuseppe Giaccone

Meyer Cancer Center

Co-authored papers 36

Paul S Meltzer

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 10

Iacopo Petrini

University of Pisa

Co-authored papers 9

Arun Rajan